GlassScriptPhysician profile
Justin A Baker
NPI 1790707925
$14,387.51
in general payments reported to CMS, 2019-2025
57 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,647 · 2020: $1,139 · 2021: $1,896 · 2022: $1,972 · 2023: $2,299 · 2024: $2,042 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,734.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,154.88 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $2,016.54 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,100.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,053.19 | 2019-2025 | |
| Dexcom, INC. | $834.52 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $634.32 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.66 | 2019-2025 | Jardiance, Spevigo, Ofev |
| Amgen INC. | $568.79 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $484.67 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $481.04 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $434.77 | 2022-2025 | |
| Lilly USA, LLC | $381.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $355.97 | 2019-2024 | Gardasil 9, Proquad, Vaxneuvance |
| Allergan, INC. | $346.98 | 2019-2020 | |
| Astellas Pharma US INC | $304.24 | 2019-2025 | Veozah, Myrbetriq |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.